Benefits and harms of sodium-glucose co-transporter-2 inhibitors (SGLT2-I) and renin-angiotensin-aldosterone system inhibitors (RAAS-I) versus SGLT2-Is alone in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.

Endocrinol Diabetes Metab · 2022 · PMC8754244 · PMID 34636161

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

In our analysis, SGLT2 inhibition compared with placebo reduced the risk of major cardiovascular outcome, but this reduction did not reach statistical significance, as this achievement was expected in a well‐treated population on renin‐angiotensin‐aldosterone system blockade.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.